France-based Orakl Oncology, a precision oncology drug discovery start-up, announced that it has raised €3M to develop its techbio platform. The company claims the platform integrates biology and real-world patient data to model tumours and speed up oncology drug development.
The funding round was led by Speedinvest, with the participation of HCVC and Verve Ventures.
“Our ambition is to become a world-leading techbio platform leveraging the smartest collection of tumour avatars to transform oncology drug development and bring faster, smarter and more cost-effective treatments to patients,” says Dr Fanny Jaulin, CEO and co-founder of Orakl Oncology.
“We are delighted with the result of this oversubscribed fundraising round, and we are very grateful to all our investors for their support,” she adds.